Prevention and management of CVD in diabetes patients in the COVID-19 era
In a special article collection of Diabetes Care, The Diabetes and Cardiovascular Disease EAS Study group has published the perspective ‘Issues of cardiovascular risk management in people with diabetes in the COVID-19 era’.
This perspective describes newly occurring cardio-renal-pulmonary organ damage induced or worsened by COVID-19 and implications for CV risk management of diabetes patients. Furthermore, challenges that may occur with use of most diabetes medications (in terms of emerging contraindications), implementation of continuous glucose monitoring, patients in the ICU requiring therapy for glycemic control, use of medication that may increase number of ACE2 receptors (there is no evidence that these medications may be harmful with respect to acquiring or worsening COVID-19) are discussed in this article.
Share this page with your colleagues and friends: